The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yue, Deng, Chao, Qiu, Zhenhua, Cao, Chenghui, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517331/
https://www.ncbi.nlm.nih.gov/pubmed/34660278
http://dx.doi.org/10.3389/fonc.2021.713530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517331/
https://www.ncbi.nlm.nih.gov/pubmed/34660278
http://dx.doi.org/10.3389/fonc.2021.713530

Ejemplares similares